Category: Data


Information for Physicians: Medical Office Review of Dhruva et al.

On February 10, the Dhruva et al. paper analyzing CATH PCI and Chest Pain registry data published in JAMA. This paper has similar conclusions to Dr. Dhruva’s presentation on this same topic in November 2019 at the American Heart Association conference. The Abiomed Medical Office has reviewed the Dhruva paper and supplement and identified a number of … Continue reading “Information for Physicians: Medical Office Review of Dhruva et al.”

Clinical Research

PROTECT IV Randomized Controlled Trial RECOVER IV Randomized Controlled Trial STEMI DTU Randomized Controlled Trial National Cardiogenic Shock Initiative (NCSI) Study DanGer Shock Randomized Controlled Trial FDA Post-Approval Studies PROTECT IV Randomized Controlled Trial The intent of the PROTECT IV Randomized Controlled Trial (RCT) is to leverage and validate the best practices learned from the … Continue reading “Clinical Research”

PROTECT Series of Clinical Studies Provides Mounting Evidence for Impella Support in High-risk PCI

Looking at the data from the PROTECT Series—PROTECT I1, PROTECT II RCT2, and PROTECT III—William O’Neill, MD, medical director of the Center for Structural Heart Disease at Henry Ford Hospital believes that “the totality of clinical data in favor of Impella supported high-risk PCI allows interventional cardiologists to be confident they are using the optimal … Continue reading “PROTECT Series of Clinical Studies Provides Mounting Evidence for Impella Support in High-risk PCI”

Publication Review: Amin Analysis on Impella and IABP

Review of Trends, Variation and Outcomes in Impella® Use Dr. Seth Bilazarian, Abiomed’s Chief Medical Officer, provides a review of the observational analysis published in Circulation and presented at AHA 2019 by Amin, et al., comparing Impella to IABP. Dr. Bilazarian notes that the study is an observational, non-FDA audited analysis that is fundamentally flawed … Continue reading “Publication Review: Amin Analysis on Impella and IABP”

Cost-effectiveness and Impella

Dr. George Vetrovec Discusses Impella Cost Effectiveness Dr. George Vetrovec, professor of medicine, emeritus, at Virginia Commonwealth University, says that physicians are increasingly concerned about cost-effectiveness as they consider treatment options for patients. He discusses data showing the cost-effectiveness of percutaneous ventricular assist devices (PVADs), including Impella. Analyses of the PROTECT II randomized controlled trial … Continue reading “Cost-effectiveness and Impella”

NCSI Findings Regarding Right Ventricular Dysfunction

About 40% of AMICS Patients Develop Right Ventricular Dysfunction Dr. Babar Basir, an interventionalist at Henry Ford Hospital and one of co-investigators for the National Cardiogenic Shock Initiative (NCSI), discusses the latest findings on right heart dysfunction from that initiative with Dr. Cathy Jeon. Dr. Basir explains that his work within the NCSI has sought … Continue reading “NCSI Findings Regarding Right Ventricular Dysfunction”